Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for investment opportunities [3]. Core Views - The company is a global leader in the methionine industry, with a robust development in specialty products. The forecasted net profit for 2025-2027 is expected to be 1.6 billion, 1.7 billion, and 2.1 billion yuan respectively, with growth rates of 29%, 11%, and 20% [3]. - The company is currently undervalued, with a reasonable valuation range for 2025 estimated between 27.6 billion and 29.1 billion yuan, and for 2026 between 30.3 billion and 33.2 billion yuan [3]. Summary by Sections Company Overview - The company is a leading global producer of animal nutrition additives, with production bases in Europe, the USA, China, and Thailand. Its main products include methionine, vitamins, and specialty products [9][15]. - The company has a strong backing from state-owned enterprises, enhancing its market position and credibility [15][22]. Methionine Market Dynamics - The methionine industry is characterized by high barriers to entry and strong demand growth. The global supply is stable, with limited new capacity expected, leading to a favorable supply-demand balance [9][15]. - The company is one of the few manufacturers capable of producing both solid and liquid methionine, with significant production capacities in both forms [9][32]. Specialty Products Development - Specialty products represent the company's second major business pillar, with a diverse product matrix that includes hundreds of products. The gross margin for specialty products is approximately 41% [9][37]. - The company is actively expanding its specialty product offerings through product localization, new product launches, and acquisitions [9][37]. Financial Performance and Forecast - The company's total revenue is projected to grow from 13.18 billion yuan in 2023 to 19.94 billion yuan in 2027, with a compound annual growth rate (CAGR) of 13.65% [3]. - The net profit is expected to rebound significantly in 2024, reaching approximately 1.2 billion yuan, driven by rising methionine prices and increased sales volumes [3][37]. Valuation and Investment Potential - The report highlights that the company's current valuation is low compared to its growth potential, with a projected P/E ratio decreasing from 20.96 in 2024 to 12.10 in 2027 [3]. - The company is well-positioned to capitalize on the growing demand for methionine and specialty products, making it an attractive investment opportunity [3].

Core Viewpoint - The approval of Andy Su's 3 billion yuan private placement aims to enhance production capacity and support sustainable development projects, reflecting the company's growth strategy in the animal nutrition sector [1][2]. Fundraising and Business Expansion - Andy Su plans to raise up to 3 billion yuan through a private placement to expand production capacity and supplement working capital [2]. - The funds will be allocated to functional products, special products, and sustainable development projects, with 1.743 billion yuan specifically earmarked for a solid methionine project [2][3]. - The company categorizes its main products into functional products (including methionine and vitamins) and special products (including feed additives) [2]. Market Demand and Growth - The global demand for methionine is projected to reach 1.7 million tons by 2024, with a compound annual growth rate (CAGR) of 4.4%, while China's demand is expected to grow from 280,000 tons in 2019 to 450,000 tons by 2024, with a CAGR of 10% [3]. - The company anticipates strong market absorption for its new production capacity due to this growing demand [3]. Financial Performance - In the first half of 2025, Andy Su reported a revenue increase of 17.23% to 8.512 billion yuan and a net profit increase of 21.82% to 740 million yuan [4]. - The sales of methionine continued to grow, driven by increased market penetration, with a 16% year-on-year increase in sales volume [4]. - The special products segment also saw a revenue increase of 9% to 2.04 billion yuan, supported by strong sales growth in ruminant and pig products [4]. Research and Development - The company is committed to increasing R&D investments in green production, biotechnology, and digital services, with R&D expenses reaching 172 million yuan in the first half of 2025 [5]. - Andy Su operates five global R&D centers with over 300 employees dedicated to research and innovation, which are crucial for supporting its dual pillar strategy [5].

安迪苏是一家全球领先的动物营养添加剂企业，主要从事动物营养添加剂的研发、生产及销售。公司股 票9月10日收盘价为9.79元/股。 核校：孙萍 募集资金净额将用于功能性产品项目（15万吨/年固体蛋氨酸项目）、特种产品项目（年产3.7万吨特种 产品饲料添加剂项目、布尔戈斯特种产品饲料添加剂项目）、可持续发展项目（丙烯酸废水处理和中水 回用项目）及补充流动资金。 公司表示，15万吨/年固体蛋氨酸项目将有效扩充中国蛋氨酸产能，优化产品结构及国内外产能布局， 是实施"双支柱"战略、巩固行业领导地位的关键举措。特种产品项目着重降本扩产，落实将特种产品作 为第二大收入驱动因素的战略规划。可持续发展项目旨在减少污染物和降低碳排放，实现节能减排目 标。 本次发行将增强公司资本实力，部分募集资金用于补充流动资金，可优化资产负债结构，缓解经营性现 金流压力，降低财务风险。从长期战略看，资金实力增强有助于公司在产业链布局、新业务开拓、技术 研发创新等方面实现优化，提升主营业务深度及广度。 ...

Group 1 - The core point of the news is that Andy Su's stock price dropped by 5.01% to 10.05 CNY per share, with a trading volume of 165 million CNY and a turnover rate of 0.60%, resulting in a total market capitalization of 26.953 billion CNY [1] - Andy Su, established on May 31, 1999, and listed on April 20, 2000, is based in Beijing and specializes in the research, production, and sales of animal nutrition additives. The revenue composition of its main business includes 76.07% from functional products and 23.93% from specialty products [1] Group 2 - From the perspective of major fund holdings, Morgan Fund has a significant position in Andy Su, with the Morgan Quantitative Multi-Factor Mixed Fund (005120) holding 15,400 shares, accounting for 0.96% of the fund's net value, ranking as the seventh largest holding. The estimated floating loss today is approximately 8,160.41 CNY [2] - The Morgan Quantitative Multi-Factor Mixed Fund (005120) was established on January 19, 2018, with a latest scale of 15.5269 million CNY. Year-to-date returns are 23.1%, ranking 3,438 out of 8,254 in its category; the one-year return is 48.11%, ranking 2,732 out of 8,037; and since inception, the return is 46.29% [2] - The fund manager, He Zhihao, has been in position for 4 years and 210 days, managing total assets of 15.43 billion CNY, with the best fund return during his tenure being 52.51% and the worst being -34.95% [2]

Core Viewpoint - The article highlights the top "profit kings" and "growth kings" in the A-share market for 2024, showcasing companies with significant net profits and growth rates, while also noting their plans for cash dividends [2][4]. Group 1: Top "Profit Kings" - The top "profit kings" in the A-share market for 2024 include China Petroleum, China Mobile, China National Offshore Oil Corporation, Kweichow Moutai, China Shenhua, CATL, Sinopec, COSCO Shipping, China State Construction, and BYD, excluding financial stocks [2]. - China Petroleum achieved a net profit of 164.68 billion yuan in 2024, a year-on-year increase of 2.0%, while China National Offshore Oil Corporation reported a net profit of 137.936 billion yuan, up 11.4% year-on-year [4]. - Kweichow Moutai's total operating revenue reached 174.144 billion yuan, growing by 15.66% year-on-year, with a net profit of 86.228 billion yuan, an increase of 15.38%. The company plans to distribute a cash dividend of 276.24 yuan per 10 shares, totaling 64.7 billion yuan for the year [4]. Group 2: Top "Growth Kings" - The top "growth kings" for 2024 include Zhengdan Co., Guangxi Energy, Siterwell, North China Pharmaceutical, Andisu, China National Machinery, Sanxiang Impression, Demingli, Huguang Co., and Qicai Chemical, excluding financial stocks and loss-recovering companies [2]. - Andisu, a leader in animal nutrition additives, reported operating revenue of 15.534 billion yuan, a year-on-year increase of 17.83%, and a net profit of 1.204 billion yuan, surging by 2208.66% [5]. - Andisu plans to enhance its R&D investment and innovate to expand its product portfolio, with a focus on growth in its methionine product line and resilience in its vitamin business [5]. Group 3: Overall Market Performance - As of April 30, 2024, 5,403 A-share companies had disclosed their annual reports, with 4,030 reporting positive net profits and 2,568 showing year-on-year growth [7]. - In the first quarter of 2025, 5,398 companies released their reports, with 4,078 reporting positive net profits and 2,955 showing year-on-year growth [7]. - Significant performance recovery was noted in sectors such as agriculture, non-bank finance, electronics, transportation, automotive, home appliances, telecommunications, retail, food and beverage, public utilities, and non-ferrous metals [7].

Core Viewpoint - Andy Su, a leading global animal nutrition company, reported strong performance in Q1 2025, with significant revenue and profit growth driven by its dual pillar strategy focusing on methionine and specialty products [1][3]. Financial Performance - In Q1 2025, the company achieved revenue of 4.3 billion yuan, a year-on-year increase of 23% [1]. - Gross profit rose by 14% to 1.27 billion yuan, while net profit surged by 67.9% to 465 million yuan [1][3]. - The functional products segment generated revenue of 3.32 billion yuan, reflecting a 29% year-on-year growth, with methionine sales volume increasing by 24% [1][4]. Business Strategy - The company is implementing a "dual pillar" strategy to solidify its leadership in the methionine market while accelerating the development of specialty products [1][5]. - To meet global methionine demand, Andy Su plans to raise up to 3 billion yuan through a private placement to fund four core projects and enhance working capital [5][6]. Production Capacity and R&D Investment - The company is expanding its production capacity, with a new solid methionine project in Fujian province expected to produce 150,000 tons annually, set to commence operations in 2027 [5][6]. - R&D expenditures have been steadily increasing, totaling 1.858 billion yuan over the past five years, with a focus on green production, biotechnology, and digital services [2][6].

Core Viewpoint - The company, Andisu, is undergoing significant capital operations, marking its largest since its reverse merger in 2015, with a focus on expanding its production capacity in the animal nutrition sector [1] Group 1: Company Overview - Andisu specializes in the research, production, and sales of animal nutrition additives, holding a leading position in the industry for several core products [3] - The company's product offerings are categorized into functional products, such as methionine and vitamins, and specialty products aimed at enhancing animal health and feed efficiency [3] Group 2: Investment Projects - The company plans to invest CNY 1.743 billion (approximately USD 246 million) in a solid methionine project with an annual capacity of 150,000 tons, accounting for 46.3% of the total fundraising amount [4] - The project will be located in Quanzhou, Fujian Province, and is expected to commence production in 2027 [4] - The liquid methionine production capacity at Andisu's Nanjing plant is currently the second largest globally, which will create synergies with the new solid methionine expansion [4] Group 3: Financial Performance - In 2024, Andisu is projected to achieve a revenue of CNY 15.53 billion (approximately USD 2.23 billion), representing a year-on-year growth of 17.83% [9] - The net profit attributable to shareholders is expected to reach CNY 1.204 billion (approximately USD 171 million), showing a dramatic increase of 2215% compared to 2023, although this is largely due to a low base effect from the previous year [9] - The company's net profit in 2023 was only CNY 52 million (approximately USD 7.4 million), a decline of nearly 96% from CNY 1.247 billion (approximately USD 178 million) in 2022 [9] Group 4: Market Dynamics - The methionine market is dominated by international giants, with a global market size projected to exceed 1.5 million tons by 2028, while the current domestic production rate is below 30% [3] - The industry has experienced a cyclical nature, with methionine prices significantly influenced by global capacity expansions, leading to an oversupply situation [10] - From 2016 to 2023, the average price of methionine in the domestic market decreased by 34% [10] Group 5: Cost and Profitability - The company's operating costs have risen sharply from CNY 7.465 billion (approximately USD 1.06 billion) in 2016 to CNY 13.669 billion (approximately USD 1.96 billion) in 2024 [12] - Despite efforts to optimize supply chain management, the pressure from rising costs, driven by high prices of key raw materials and global supply chain disruptions, has significantly impacted profitability [12] - The gross margin has decreased from 47.43% in 2016 to 21.38% in 2023, with a recovery to 30.21% anticipated in 2024 [10]

星标 ★ IPO日报 精彩文章第一时间推送 近期，全球动物营养添加剂龙头蓝星安迪苏股份有限公司（600299.SH，下称"安迪苏"）发布公告，公司拟向特定对象发行预计发行数量不超过8 亿股公司股票，募集资金总额不超过30亿元，用于四大核心项目及补充流动资金。 4月16日，该事项获上交所受理。 不过，作为动物必需氨基酸，蛋氨酸市场长期被赢创、住友、诺伟司等国际巨头垄断。兴业证券研报显示，全球蛋氨酸市场规模预计2028年将突破 150万吨，当前国产化率不足30%。 在此次募投项目中，公司拟使用17.43亿元，投入年产能为15万吨的固体蛋氨酸项目，占总募资额的46.3%，进一步扩产。该项目实施地点在福建 省泉州市，预计于2027年投产。 值得关注的是，安迪苏南京工厂的液体蛋氨酸产能已达全球第二，与此次固体蛋氨酸的扩产将形成协同效应。 这是继2015年通过反向收购重组上市后，公司规模最大的资本运作。 制图：佘诗婕 发挥协同效应 据悉，安迪苏主要从事动物营养添加剂的研发、生产及销售。公司在动物饲料添加剂领域中，多个核心产品的产业规模与技术水平处于行业领先地 位。 具体来看，公司产品主要分为两类，包括功能性产品和特种产品 ...

Core Viewpoint - The company, Andisu, is progressing with its private placement fundraising project, aiming to raise up to 3 billion yuan for various strategic initiatives, including functional and specialty product projects, sustainable development, and working capital [1][2]. Group 1: Fundraising and Strategic Development - The private placement aims to raise a total of no more than 3 billion yuan, with net proceeds allocated to functional products, specialty products, sustainable development projects, and working capital [2][3]. - The company has categorized its main business products into functional products, which include methionine, vitamins, and ammonium sulfate, and specialty products, which focus on enhancing animal health and feed quality [2][3]. Group 2: Financial Performance and Recovery - After experiencing a significant decline in performance in 2022 and 2023, the company is expected to return to normal operations in 2024, with projected revenues of 15.534 billion yuan and a net profit of 1.204 billion yuan [1][6]. - The company reported a 24% increase in revenue from functional products in 2024, achieving 11.622 billion yuan, while specialty products generated 3.913 billion yuan, reflecting a 4% growth [2][5]. - The company’s net profit for 2024 is projected to increase by 2208.66% compared to the previous year, indicating a strong recovery [6]. Group 3: Market Position and Growth - The company has increased its market share in methionine from 23% in 2012 to 28% in 2023, solidifying its leadership position in the industry [5]. - The company is expanding its global market presence, with double-digit sales growth in Europe, North America, and Asia in 2024 [3]. - The price of methionine has risen by approximately 8.14% since 2025, which is expected to positively impact the company's performance [3].

Core Viewpoint - The article highlights the recent trend of public fund managers increasing their positions in companies with strong profit growth, particularly in the livestock and energy sectors, as they adjust their portfolios following the disclosure of 2024 annual reports [1][4]. Group 1: Livestock Sector Performance - Companies in the livestock sector, such as Muyuan Foods, have shown significant performance improvements, attracting attention from fund managers. Muyuan Foods reported a revenue of 137.947 billion yuan, a year-on-year increase of 24.43%, and a net profit of 17.881 billion yuan, marking a turnaround from losses [4][5]. - Fund managers have notably increased their holdings in Muyuan Foods, with notable increases from various ETFs managed by Huatai-PineBridge and other funds [4][5]. - The animal nutrition additive producer, Andisu, also saw a revenue of 15.534 billion yuan, up 17.83%, and a net profit of 1.204 billion yuan, reflecting a substantial year-on-year growth of 2208.66% [4][5]. Group 2: High Dividend Stocks - High dividend-paying industry leaders, such as Fuyao Glass, Muyuan Foods, and Baofeng Energy, are favored by institutional investors, with expected cash dividends exceeding 2 billion yuan [7]. - For instance, the waterproofing company Oriental Yuhong saw significant increases in holdings from national social security funds and various mutual funds, indicating strong institutional interest [7]. Group 3: Chemical and Energy Sector Insights - Companies in the chemical and energy sectors, including Chuanjin Nuo and Shanghai Petrochemical, have also reported strong performance, attracting fund manager interest [8][9]. - Fund managers believe that industries facing overcapacity, such as photovoltaics and chemicals, may benefit from policy support aimed at supply-side reforms, potentially leading to a market turning point [9]. - Baofeng Energy, a leader in the coal chemical industry, has seen new major shareholders, indicating growing institutional confidence in the sector [8][9].